Prospective Assessment of Pituitary Function in Patients with Macroprolactinoma Treated with Cabergoline.

Prospective Assessment of Pituitary Function in Patients with Macroprolactinoma Treated with Cabergoline.

Dades bibliogràfiques
Autors principals:	Karavitaki, N, Wass, J
Format:	Conference item
Publicat:	2010

Ítems similars

Does hypopituitarism recover when macroprolactinomas are treated with cabergoline?
per: Karavitaki, N, et al.
Publicat: (2013)

Does hypopituitarism recover when macroprolactinomas are treated with cabergoline?
per: Karavitaki, N, et al.
Publicat: (2013)

A macroprolactinoma becoming resistant to cabergoline and developing atypical pathology
per: Emilia Sbardella, et al.
Publicat: (2016-10-01)

Early Prediction of Long-Term Response to Cabergoline in Patients with Macroprolactinomas
per: Youngki Lee, et al.
Publicat: (2014-09-01)

Cabergoline therapy for Macroprolactinoma during pregnancy: A case report
per: Shahzad Hira, et al.
Publicat: (2012-10-01)

The outcome of macroprolactinomas resistant to dopamine agonists
per: Coculescu, M, et al.
Publicat: (2005)

Efficacy and safety of rapid escalation of cabergoline in comparison to conventional regimen for macroprolactinoma: A prospective, randomized trial
per: Ashu Rastogi, et al.
Publicat: (2012-01-01)

Clinical Outcome of Invasive Pituitary Prolactinomas Treated with Cabergoline
per: Bassam M Flamerz Arkawazi
Publicat: (2020-01-01)

Valvular heart disease and the use of cabergoline for the treatment of prolactinoma.
per: Herring, N, et al.
Publicat: (2009)

A case of macroprolactinoma encasing an internal carotid artery aneurysm, presenting as pituitary apoplexy.
per: Soni, A, et al.
Publicat: (2008)

Macroprolactinomas and Nonfunctioning Pituitary Adenomas and Pregnancy Outcomes.
per: Lambert, K, et al.
Publicat: (2017)

Macroprolactinomas and nonfunctioning pituitary adenomas and pregnancy outcomes
per: Lambert, K, et al.
Publicat: (2017)

Cabergoline-Induced Pneumocephalus Following Treatment for Giant Invasive Macroprolactinoma Presenting With Spontaneous Cerebrospinal Fluid Rhinorrhea
per: Souha S Elabd, et al.
Publicat: (2018-02-01)

Cabergoline-induced mania in a patient of pituitary microadenoma
per: Satyakam Mohapatra, et al.
Publicat: (2017-01-01)

An aggressive cabergoline-resistant, temozolomide-responsive macroprolactinoma due to a germline SDHB pathogenic variant in the absence of paraganglioma or pheochromocytoma
per: Ali S. Alzahrani, et al.
Publicat: (2023-12-01)

Can we ever stop imaging in surgically treated and radiotherapy-naive patients with non-functioning pituitary adenoma?
per: Reddy, R, et al.
Publicat: (2011)

A patient with a germline SDHB mutation presenting with an isolated pituitary macroprolactinoma
per: Michelle Maher, et al.
Publicat: (2018-07-01)

Non-adenomatous pituitary tumours.
per: Karavitaki, N, et al.
Publicat: (2009)

Diagnosis and management of prolactinomas and non-functioning pituitary adenomas.
per: Rogers, A, et al.
Publicat: (2014)

Nonfunctioning pituitary adenomas: the Oxford experience.
per: Wass, J, et al.
Publicat: (2009)

Growth hormone replacement in patients with non-functioning pituitary adenoma treated solely by surgery is not associated with increased risk of tumour recurrence.
per: Arnold, J, et al.
Publicat: (2008)

GH replacement in patients with non-functioning pituitary adenoma (NFA) treated solely by surgery is not associated with increased risk of tumour recurrence.
per: Arnold, JR, et al.
Publicat: (2009)

The postoperative monitoring of nonfunctioning pituitary adenomas.
per: Wass, J, et al.
Publicat: (2011)

The postoperative monitoring of nonfunctioning pituitary adenomas
per: Wass, J, et al.
Publicat: (2011)

Treatment of pituitary tumors: history.
per: Thanabalasingham, G, et al.
Publicat: (2005)

VISUAL FIELD DEFECTS SECONDARY TO CABERGOLINE USE IN A PATIENT WITH PITUITARY TUMOR
per: sylvia andrea araneda, et al.
Publicat: (2015-02-01)

Pituitary apoplexy in an adolescent male with macroprolactinoma presenting as middle cerebral artery territory infarction
per: Pankaj Agrawal, et al.
Publicat: (2022-12-01)

Efficacy of cabergoline therapy in patients with non-functioning pituitary adenomas: A single center clinical experience
per: Guadalupe Vargas-Ortega, et al.
Publicat: (2022-07-01)

Successful Management of a Giant Pituitary Lactosomatotroph Adenoma Only with Cabergoline
per: Emre Bozkirli, et al.
Publicat: (2013-01-01)

Bromocriptine or cabergoline induced pituitary apoplexy: Rare but life-threatening catastrophe
per: Pratibha Singh, et al.
Publicat: (2011-01-01)

The modern management of macroprolactinomas.
per: Grossman, A
Publicat: (1991)

Increased prevalence of high Body Mass Index in patients presenting with pituitary tumours: severe obesity in patients with macroprolactinoma
per: DL Goede, et al.
Publicat: (2006-04-01)

Retrospective assessment of the use of extended-release cabergoline in the management of equine pituitary pars intermedia dysfunction
per: Tania Sundra, et al.
Publicat: (2024-03-01)

Nonsurgical cerebrospinal fluid rhinorrhea in invasive macroprolactinoma: incidence, radiological, and clinicopathological features.
per: Suliman, S, et al.
Publicat: (2007)

No link to cardiac valvulopathy was seen in cabergoline treated patients
per: K Dharshini, et al.
Publicat: (2012-10-01)

MANAGEMENT OF ENDOCRINE DISEASE: Pituitary tumour apoplexy.
per: Capatina, C, et al.
Publicat: (2014)

Recurrence of hyperprolactinaemia following discontinuation of dopamine agonist therapy in patients with prolactinoma occurs commonly especially in macroprolactinoma.
per: Barber, T, et al.
Publicat: (2011)

Reply to Commentary on "Pituitary apoplexy in an adolescent male with macroprolactinoma presenting as middle cerebral artery territory infarction"
per: Pankaj Agrawal, et al.
Publicat: (2023-03-01)

Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK).
per: Fernandez, A, et al.
Publicat: (2010)

Macroprolactinoma in an adolescent female with primary amenorrhoea
per: Ning Zhang, et al.
Publicat: (2024-12-01)